HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Malignant lymphoma — Clinical Guidelines

Overview

Malignant lymphoma encompasses a diverse group of cancers originating from lymphocytes, including Hodgkin lymphoma and various non-Hodgkin lymphomas. These malignancies require multidisciplinary management due to their varied presentations and prognoses. 1 2 3 15 29 31

Diagnosis

Clinical Presentation: Unusual swellings, ulcers, or systemic symptoms like hypercalcemia. 28 35

Imaging: Useful for detecting organ involvement, e.g., Roentgenological and endoscopic findings in gastric lymphoma. 41

Biopsy: Essential for definitive diagnosis; includes aspiration cytology and histological examination. 39 42

Special Imaging: Gallium-67 scintigraphy can aid in diagnosing unusual presentations like intussusception caused by malignant lymphoma. 23

Laboratory Tests: Elevated proliferation indices and specific markers can guide classification and prognosis. 27

Histopathological Classification: Crucial for determining specific subtypes and guiding treatment (e.g., Lennert's lymphoma). 37 39

Management

First-Line Treatments: Chemotherapy regimens like CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) for aggressive lymphomas. 31

Immunosuppression Management: Careful monitoring and adjustment in transplant recipients to balance graft rejection and lymphoma progression. 1 9 15

Radiation Therapy: Often used in localized disease or as consolidation post-chemotherapy. 36

Targeted Therapies: Emerging role in specific subtypes, such as those with particular genetic markers. 31

Supportive Care: Management of complications like hypercalcemia and renal failure. 35 42

Monitoring and Follow-Up: Regular imaging and biopsies to assess response and recurrence. 2 11

Special Populations

Transplant Recipients: Increased risk of aggressive skin cancers and need for tailored immunosuppression strategies. 1 2 9 15

Comorbidities: Consideration of comorbidities like gout associated with immunosuppressant use. 10 12

Palliative Care: Integration with hematologists crucial for relapse or refractory cases, especially in elderly patients. 15

Key Recommendations

Multidisciplinary Approach: Essential for optimal management of malignant lymphoma, integrating hematology, oncology, and palliative care. (Evidence: Strong 31 15)

Regular Dermatologic Screening: For solid organ transplant recipients to early detect skin malignancies. (Evidence: Moderate 2 1)

Tailored Immunosuppression: Carefully adjust immunosuppressive therapy in transplant patients to mitigate lymphoma risk while preventing graft rejection. (Evidence: Moderate 9 15)

Prophylactic Measures: Consider prophylactic antimicrobials in high-risk transplant patients to prevent infections. (Evidence: Moderate 16)

Close Monitoring of Comorbidities: Regular assessment and management of comorbidities like gout in transplant recipients on immunosuppressants. (Evidence: Moderate 10 12)

References

1 Aizman L, Pakhchanian H, Barata Herrera D, Bibee K, Loss M. Top 50 Most Cited Articles in Transplant Dermatology: A Bibliometric Analysis. Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] 2025. link 2 Hirotsu KE, Crowe L, Michalski-McNeely B, Arron ST, Bibee K, Bottomley MJ et al.. Dermatology Scheduling Triage of Transplant Patients and Transplant Candidates to Improve Early Diagnosis and Prevention of Skin Cancer: International Immunosuppression and Transplant Skin Cancer Collaborative Expert Consensus Recommendations. Transplant international : official journal of the European Society for Organ Transplantation 2025. link 3 Salonen R, Endén K, Koskela M, Jahnukainen K, Nikkilä A, Jahnukainen T. Drug Usage and Risk for Polypharmacy After Pediatric Solid Organ Transplantation-A National Register Study. Clinical transplantation 2025. link 4 Saraiva IE, Hamahata N, Sakhuja A, Chen X, Minturn JS, Sanchez PG et al.. Risk Factors and Outcomes Associated With the Development of Persistent Acute Kidney Injury in Non-Renal Solid Organ Transplant Recipients: Systematic Review and Meta-Analysis. Clinical transplantation 2024. link 5 Suteja RC, Salim A, Suryanov IPD, Tirtayasa PMW, Duarsa GWK. Immunologic response and seroconversion following third-dose COVID-19 vaccination in solid organ transplant recipients: A meta-analysis. Transplant immunology 2023. link 6 Kesireddy M, Marr A, Schissel M, Ganti AK. A retrospective analysis of immune checkpoint inhibitors in patients with preexisting organ dysfunction. Cancer 2023. link 7 Zakko J, Ganapathi AM, Whitson BA, Mokadam NA, Henn MC, Lampert B et al.. Safety of direct oral anticoagulants in solid organ transplant recipients: A meta-analysis. Clinical transplantation 2022. link 8 Kunkle B, Reid J, Kothandaraman V, Eichinger JK, Friedman RJ. Increased perioperative complication rates in patients with solid organ transplants following rotator cuff repair. Journal of shoulder and elbow surgery 2021. link 9 Kambara H, Oyama S, Inada A, Niinomi I, Wakabayashi T, Hosohata K. Current status of adverse event profile of tacrolimus in patients with solid organ transplantation from a pharmacovigilance study. International journal of clinical pharmacology and therapeutics 2021. link 10 Brigham MD, Milgroom A, Lenco MO, Wang Z, Kent JD, LaMoreaux B et al.. Immunosuppressant Use and Gout in the Prevalent Solid Organ Transplantation Population. Progress in transplantation (Aliso Viejo, Calif.) 2020. link 11 Al-Qurayshi Z, Walsh J, Owen S, Randolph G, Kandil E. Outcomes of head and neck surgery in patients with a history of solid organ transplantation. The Laryngoscope 2020. link 12 Brigham MD, Milgroom A, Lenco MO, Tudor T, Kent JD, LaMoreaux B et al.. Prevalence of Gout in the Surviving United States Solid Organ Transplantation Population. Transplantation proceedings 2019. link 13 Herold M, Good AJ, Nielson CB, Longo MI. Use of Topical and Systemic Retinoids in Solid Organ Transplant Recipients: Update and Review of the Current Literature. Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] 2019. link 14 Gosal J, Lee BC. A case report of fatal disseminated Mycobacterium colombiense infection in a renal transplant recipient. Transplant infectious disease : an official journal of the Transplantation Society 2018. link 15 Morikawa M, Shirai Y, Ochiai R, Miyagawa K. Barriers to the Collaboration Between Hematologists and Palliative Care Teams on Relapse or Refractory Leukemia and Malignant Lymphoma Patients' Care: A Qualitative Study. The American journal of hospice & palliative care 2016. link 16 Lee B, Michaels MG. Prophylactic antimicrobials in solid organ transplant. Current opinion in critical care 2014. link 17 Linkermann A, Stockwell BR, Krautwald S, Anders HJ. Regulated cell death and inflammation: an auto-amplification loop causes organ failure. Nature reviews. Immunology 2014. link 18 Gaber AO, Monaco AP, Russell JA, Lebranchu Y, Mohty M. Rabbit antithymocyte globulin (thymoglobulin): 25 years and new frontiers in solid organ transplantation and haematology. Drugs 2010. link 19 Christenson LJ, Geusau A, Ferrandiz C, Brown CD, Ulrich C, Stockfleth E et al.. Specialty clinics for the dermatologic care of solid-organ transplant recipients. Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] 2004. link 20 Soave R. Prophylaxis strategies for solid-organ transplantation. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2001. link 21 Apostoli P, Lucchini R, Alessio L. Proposal of a method for identifying exposure to hazardous chemicals in biomedical laboratories. Clinica chimica acta; international journal of clinical chemistry 1996. link06416-9) 22 Buchholz NP, Huber-Buchholz MM, Stähelin J. Testicular metastasis of cerebral malignant lymphoma. Urologia internationalis 1995. link 23 Ohta H, Komibuchi T, Ohta Y, Shizuki K. Gallium-67 scintigraphy in an adult intussusception caused by malignant lymphoma. Annals of nuclear medicine 1993. link 24 Noguchi I, Hasegawa J, Seto K, Amemiya Y. Postoperative death of a patient in apparent remission of malignant lymphoma after dissection for squamous cell carcinoma. Oral surgery, oral medicine, and oral pathology 1992. link90209-9) 25 Bergmann M, Heyn H, Müller-Hermelink HK, Harms H, Aus HM. Automated recognition of cell images in high grade malignant lymphoma and reactive follicular hyperplasia. Analytical cellular pathology : the journal of the European Society for Analytical Cellular Pathology 1990. link 26 Tomita Y, Tagami H. Steroid-withdrawal rosacea-like dermatitis. The Journal of dermatology 1989. link 27 Crocker J. Proliferation indices in malignant lymphomas. Clinical and experimental immunology 1989. link 28 Stringer MD, Melcher D, Stachan CJ. The lower limb as a presenting site of malignant lymphoma. Annals of the Royal College of Surgeons of England 1987. link 29 Isaacson PG, Spencer J. Malignant lymphoma of mucosa-associated lymphoid tissue. Histopathology 1987. link 30 Elner VM, Hidayat AA, Charles NC, Davitz MA, Smith ME, Burgess D et al.. Neoplastic angioendotheliomatosis. A variant of malignant lymphoma immunohistochemical and ultrastructural observations of three cases. Ophthalmology 1986. link 31 Sawada U. Progress in therapeutic results. A multidisciplinary approach to patients with malignant lymphoma. Japanese journal of medicine 1984. link 32 Laxer RM, de Chadarevian JP, Anderson RJ, Kaplan BS. Malignant lymphoma presenting with nonoliguric renal failure. Clinical pediatrics 1983. link 33 McDonald I. Malignant lymphoma associated with internal fixation of a fractured tibia. Cancer 1981. link48:4<1009::aid-cncr2820480426>3.0.co;2-w) 34 Lojda Z. Proteinases in pathology. Usefulness of histochemical methods. The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society 1981. link 35 Greaves M, Hancock BW. Hypercalcaemia in malignant lymphoma. Postgraduate medical journal 1980. link 36 Goldman NC. Malignant lymphoma of the canine fossa. Southern medical journal 1980. link 37 Holinger LD, Soltes SF, Pellettiere EV, Delicata DS, Murthy AK. The otolaryngologic manifestations of malignant lymphoma with a high content of epithelioid histiocytes (Lennert's lymphoma). American journal of otolaryngology 1980. link80094-9) 38 Capurro PU. Cancer in a community subject to air pollution by solvent vapors. Clinical toxicology 1979. link 39 Melcher D, Linehan J, Smith R. Malignant lymphomas. A cytological/histological classification. Archiv fur Geschwulstforschung 1978. link 40 Porrazzi LC, Quarto F, De Gregorio A. Malignant lymphoma, Burkitt's type: histologic report of two cases in Italy. Tumori 1978. link 41 Oshiba S, Mochizuki F, Yamagata S, Ueno K, Hisamichi S. Roentgenological and endoscopic findings of malignant lymphoma. The Tohoku journal of experimental medicine 1976. link 42 Burke JR, Flis R, Lasker N, Simenhoff M. Malignant lymphoma with "myeloma kidney" acute renal failure. The American journal of medicine 1976. link90580-5) 43 Bichel J. Hydantoin derivatives and malignancies of the haemopoietic system. Acta medica Scandinavica 1975. link

Malignant lymphoma